FINANCING PROPOSAL SYNOPSIS

Financing & Investment Risk Department

Page 1 of 9
May 8, 2014
FIRD/CBG/MFC/149/2014
CUSTOMER NAME: BROOKES PHARMA (PRIVATE) LIMITED-[BPPL]
DOMICILE
Branch
Main Branch, Karachi
Profit Centre CBG (South) Customer Group Brookes Pharma
CUSTOMER CLASSIFICATION
Corporate Sector
Pharma & Healthcare
Proprietorship Public Limited Unlisted
SME Industry Pharmaceutical Partnership Public Limited Listed
Retail Category LSM Pvt. Limited Other
OBLIGOR RISK RATING SCORE
Rating Assigned By CBG Rating Assessed By FIRD Rating History
Rating 3 Rating 3 Previous Current
Score 75 Score 73 Rating 4 Rating 3
Class Good Class Good Score 68 Score 73
LARGE SCALE & RISK CONCENTRATION
BPPL At ORRS-3 Group At Weighted ORRS-3 Sector Concentration 30/04/2014 (Rs. Mn.)
Exposure Funded Max. Exposure Funded Max. Portfolio Sector
Permit 480 675 Permit 800 1,200 Limits 43,006 1,428 3.32%
Existing* 461 461 Existing 465 465 O/s 30,024 900 3.00%
Cushion 19 214 Cushion 335 735 Industry Concentration 30/04/2014
*& Proposed
Limits 1,428 O/s. 900
PROPOSAL NATURE ACCOUNT CBGs STRATEGY TERMS & CONDITIONS
Fresh Temp. Extension Grow
Terms & Conditions as mentioned in Annexure
A forms an integral part of this synopsis.

Enhancement Modification Maintain
Renewal Restructuring Exit

GROUP EXPOSURE
(PKR in Millions)
Client Name Limit Amount Outstanding Amount Risk Rating

Funded Non Funded Total
Funded Non Funded Total
Pharma Logistics
25 - 25 4 - 4 3/Good
Brookes Pharma (Pvt) Ltd
281 (90) 281 207 41 248 3/Good
Total 306 (90) 306 211 41 252

FINANCING LIMIT STRUCTURE
(PKR in Millions)
Sr.
No.
Financing Facility
Existing
Limit
O/s
Amount
Proposed
Limit
Recommen
ded
Limit
New/
Extension/
Renewal
Proposed
Profit/
Comm.
Limit
Expiry
1
DM (Sale & Purchase Back)-I
142.5 137.5 137.5 137.5 Review MK+2.1%
30-10-18
2 Murabaha (Max 120 days) 75.0 24.9 75.0 75.0 Renewal MK+2%
31-05-15
2(a) Foreign LC (Sight/U/Accp) (75.0) 30.7 (75.0) (75.0) Renewal 0.15%
31-05-15
2(b)
LG (Performance)
(15.0) 10.2 (15.0) (15.0) Renewal APSOC
31-05-15
3 DM (Fleet Financing)-I 39.5 39.5 39.5 39.5 Review 6MK+2%
04-09-16
4 DM (Fleet Financing)-II 23.5 5.4 18.9 18.9 Review 6MK+2%
04-09-16
5
DM (Sale & Purchase Back)-II
[FRESH]
- - 190.0 190.0 New MK+2.1%
6 years
Total
280.5 248.2 460.9 460.9


PURPOSE
1
Diminishing Musharika-I
[Sale & Purchase Back]
This facility is requested for review. It was earlier approved to settle principal
component of term finance facility of Pak Kuwait Investment Company (PKIC).
FINANCING PROPOSAL SYNOPSIS
Financing & Investment Risk Department
Page 2 of 9
2
Murabaha
[Max 120 days]
This facility was allowed for retirement of import documents approved through LC
Sight & for local procurement of raw material. Raw Materials include packing
material and chemicals used in Pharma manufacturing with minimum shelf life of
one year. However, Murabaha will not be available for retirement of import
documents pertaining to machinery. Local purchases through Murabaha shall not
exceed 1/3
rd
of the approved limit i.e. Rs.25 Million.
2
(a)
Letter of Credit
[Foreign/Sight/Usance]
LC facility was granted for import of raw materials as mentioned in Murabaha
section along with machinery/equipment which shall not exceed 15% of the LC
limit at any point in time.
LC Sight can be retired through follow-on Murabaha facility; however, LC Usance
shall be retired through follow-on Acceptance with a maximum tenor of 120 days.
Acceptance to be retired from customers own resources.
Moreover documents for import of machinery will be retired by the customer from
their own sources.
2(b)
LG (Performance) LG facility was earlier approved for issuance of Performance Guarantee in favor of
government/semi government organizations for supply of medicines and for
various contracts.
3 &
4
DM (Fleet Financing)-I & II Facility was allowed for procurement of new, locally assembled & imported
TOYOTA/SUZUKI/HONDA cars for business use.
5
DM (Sale & Purchase
Back)-II [FRESH]
This fresh facility is requested for entire settlement of principal portion of long
term loans and leasing facilities of Pak Brunei Investment Co, Pak Gulf Leasing,
Bank of Punjab and Orix Leasing Limited.

Maximum tenor for requested DM-II facility is six year inclusive of one year grace
period. During grace period only profit will be paid on monthly basis. Principal
installments will be paid in arrears from 13
th
month in equal sixty monthly
installments.
SECURITY
1
Diminishing Musharika
[Sale & Purchase Back]
1
st
Pari Passu charge on all present and future fixed assets (land, building and plant
and machinery) with 25% risk margin amounting to Rs. 200 Million.
2
Murabaha
[Max 120 days]
1
st
Pari Passu chage over present and future stock in trade and trade debts with
25% with risk margin amounting to Rs.100 Million.
2 (a)
Letter of Credit
[Foreign]
[Sight/Usance]
a. Lien over import documents.
b. Accepted Bill of Exchange for LC Usance.
c. Security as mentioned in Murabaha section.
2
(b)
LG (Performance) a. 20% cash margin
b. Counter Guarantee of BPPL
c. Security as available under Murabaha facility.
3 & 4

DM (Fleet Financing)-I & II a) 10% & 20% equity participation for locally assembled and imported
vehicles respectively in the shape of security deposit.
b) Title over DM financed asset (vehicle) is to be registered exclusively in
favor of Burj Bank Limited in Excise & Taxation Office (ETO).
c) 06 Post Dated Cheques (PDC)
5
DM (Sale & Purchase
Back)-II [FRESH]
1
st
Pari Passu charge on all present and future fixed assets (land, building and plant
& machinery) with 25% risk margin that is, PKR 267 Million.

(The underlying DM assets are mentioned in Annexure-B with DM sharing ratio of 90:10).
Supplemental Security All the facilities (existing and proposed) are secured through Personal Guarantees
of all the directors of the company with PNWS. Directors PNW is reported at
Rs.172 Million.
Repayment Sources Primary Sources: Companys cash flows
Secondary Sources: Refinancing from other lenders
Tertiary Sources: Through sale of stocks/fixed assets and/or calling the PG of directors.


FINANCING PROPOSAL SYNOPSIS
Financing & Investment Risk Department
Page 3 of 9
FINANCIAL HIGHLIGHTS:

AUDITED FINANCIALS M. ACC FINANCIAL PROJECTIONS
(Rs. in Millions) June 11 June 12 June 13 Dec 13 June 14 June 15
June 16 June 17 June 18
INCOME STATEMENT
Net Revenue 1,401.7 1,610.3 1,959.8 1,154.1 2,500.0 3,000.0 3,600.0 4,300.0 5,200.0
Cost of Goods Sold 855.2 973.2 1198.1 710.3 1,525.0 1,830.0 2,196.0 2,623.0 3,172.0
Gross Profit 546.3 637.1 761.6 443.7 975.0 1,170.0 1,404.0 1,677.0 2,028.0
Operating expenses 401.6 455.5 564.9 319.9 700.0 840.0 1,000.0 1,174.0 1,343.0
Operating Profit (EBIT) 144.7 181.6 196.7 123.7 295.0 330.0 404.0 538.0 684.7
Finance Cost 107.1 112.8 119.7 76.0 150.0 140.0 120.0 100.0 70.0
Profit Before Taxes 58.9 85.6 95.4 52.4 145.0 215.0 314.0 438.0 654.7
Net Income After Taxes 44.9 69.5 75.8 40.8 104.4 161.8 229.9 309.7 471.4
BALANCE SHHET
Inventory Level 292.0 305.0 327.3 395.4 395.3 465.0 550.0 645.0 755.0
Trade Receivables/ Debtors 169.5 183.7 196.1 224.5 219.5 250.0 275.0 310.0 350.0
Other Current Assets 202.1 235.6 251.1 308.8 280.4 314.7 380.0 396.5 523.3
Total Current Assets 663.6 724.3 774.5 928.7 895.2 1,029.7 1,205.0 1,351.5 1628.3
Property, Plant & Equipment 817.2 883.8 1,264.7 1,340.7 1,388.0 1400.0 1,425.0 1,470.0 1600.0
Total Non Current Assets 817.2 883.8 1,267.7
1,340.7 1,388.0 1,400.0 1,425.0 1,470.0 1,600.0
Total Assets 1,480.8 1,608.1 2,039.2
2,269.4 2,283.2 2429.7 2,630.0 2,821.5 3,228.3
Short Term Bank Borrowing 117.8 142.3 150.8 369.3 279.8 279.8 279.8 179.0 100.0
Trade Payable/ Creditors 115.1 121.9 176.3 211.9 300.0 400.0 500.0 600.0 700.0
CP of LT bank Borrowing 113.9 150.4 243.2 246.1 - - - - -
Other Current Liabilities 31.7 44.9 58.6 54.6 40.6 53.2 84.1 128.2 183.3
Total Current Liabilities 378.5 459.5 628.9 881.9 620.4 733.0 863.9 907.2 983.3
Long Term Bank Borrowing 423.0 395.1 580.7 513.0 737.0 610.1 450.6 289.5 149.3
Other Long Term Liabilities 78.3 82.9 83.3 87.3 75.0 74.0 73.0 72.5 72.0
Total Long Term Liabilities 501.3 478.0 664.0 600.3 812.0 684.1 523.6 362.0 221.3
Total Liabilities 879.8 937.5 1,292.9
1,482.2 1,432.4 1,417.1 1,387.5 1,269.2 1,204.6
Equity (Excluding RR & SL) 452.7 522.2 598.0 638.9 702.4 864.2 1,094.2 1,403.9 1,875.3
Revaluation Reserve 148.2 148.2 148.2 148.2 148.2 148.2 148.2 148.2 148.2
Total 600.9 670.4 746.2 787.1 850.6 1,012.4 1,242.4 1,552.1 2,023.5
FINANCIAL RATIOS
EBITDA 235.1 272.2 296.1 163.7 378.2 439.0 519.5 626.2 820.7
Cash Conversion Cycle (CCC) 111 days 107 days 86 days
- 65 days 44 days 36 days 31 days 29 days
Gross Margin 39% 40% 39% 38% 39% 39% 39% 39% 39%
Operating Profit margin 10% 11% 10% 11% 12% 11% 11% 13% 13%
Net Profit Margin 3% 4% 4% 4% 4% 5% 6% 7% 9%
Current Ratio 1.7 1.6 1.2 1.0 1.4 1.4 1.3 1.5 1.6
Debt Services Coverage Ratio 1.0 1.0 0.8 0.5 2.5 3.1 4.3 6.2 11.7
Finance Cost Coverage Ratio 1.6 1.7 1.8 1.6 1.9 2.5 3.6 5.3 10.3
Bank Borrowings/Equity 1.5 1.3 1.6 1.8 1.4 1.0 0.6 0.3 0.1
Total Liab./Equity 1.9 1.8 2.1 2.3 2.0 1.6 1.2 0.9 0.6
Financial Analysis For the year ending 30
th
June 2013
Financial risk assessment of BPPL is based on audited financials (FY11 to FY13), management accounts (Dec 2013) and
projections (FY14-FY18). BPPLs financials are audited by Bilwani & Co.
Income Statement
In FY13, BPPL achieved a growth of 22% in sales volume, which is recorded at Rs.1,959.8 Million (FY12: Rs.1,610.3 Million).
This growth is even greater than that of FY12, which was 15%. Gross Profit is reported at Rs.761.6 Million with stagnant
margin of 39%. Operating expenses are registered with slight enhancement at Rs.564.9 Million (FY12: Rs.455.5 Million).
Operating profit margin remains stagnant at 10% for the period under consideration. During FY13, BPPL has earned other
income in the shape of sales of scrap sales, exchange gain and profit on deposits to the extent of Rs.18.4 Million in FY13
(FY12: Rs.16.7 Million). During FY13, BPPL has massively incurred capex through lease finances, which boosted finance cost
of the company, which is recorded at Rs.119.7 Million (FY12: Rs.112.8 Million). Growth in sales volume has impacted net
profit of the company, which is reported at Rs.75.8 Million (FY12: Rs.69.5 Million). In net margin terms, it hovers around 4%
for the period under review.
Balance Sheet
Total balance sheet size grew by 27% and stands at Rs. 2.04 Billion (FY12: Rs. 1.61 Billion). Within current assets category,
stocks level has enhanced to Rs.327.3 Million as against Rs. 305.0 Million in FY12, while trade debts have enhanced to Rs.
196.1 Million from Rs. 183.9 Million in FY12. These enhancements are justified in view of growing sales volume. Movement
FINANCING PROPOSAL SYNOPSIS
Financing & Investment Risk Department
Page 4 of 9
in other items of current assets is only nominal. Due to capex incurred by BPPL in FY13, tangible fixed assets including
capital work in progress is recorded at Rs. 1,264.7 Million (FY12: Rs. 883.8 Million).

Current liabilities of BPPL are recorded at Rs. 628.9 Million in FY13 (FY12: Rs. 459.5 Million). BPPLs reliance on short term
bank borrowing is adequate as it experiences enhancement by 6% and booked at Rs. 150.8 Million (FY12: Rs. 142.3 Million),
which is understandable in view of growing EBITDA. Overseas creditors balance has enhanced to Rs. 149.5 Million from Rs.
95.7 Million in FY12. Long term bank borrowing level has enhanced to Rs. 580.5 Million from Rs. 395.1 Million in FY12. Net
equity of the BPPL has jumped to Rs. 598.0 Million owing to retention of net profit.

Cash Conversion Cycle (CCC) of the company has reduced to 86 days. Our analysis suggests that due to better inventory and
receivable management, inventory and receivable turnover days have reduced. Current ratio of the company has slightly
decreased. Due to increase in long term bank borrowing, leverage and debt-equity ratios have enhanced. DSCR & FCCR are
more or less stagnant at 1.0 & 1.7 respectively.
Management Accounts (1FFY14)
During six months ending in Dec 31, 2013, BPPL has achieved sales volume of Rs.1.154 Billion. Gross Profit in margin terms
has reduced to 38%. BPPL has posted profit after taxes (PAT) of Rs.40.9 Million as on Dec 31, 2014. Operating and net
profits in term of margin remained stagnant at 11% and 4% respectively. Stocks & trade debts continue to be reported at
higher levels owing to growth in sales volume. It is to be noted that short term bank borrowing level, which was earlier
reported at Rs.150.8 Million, has enhanced to Rs.369.3 Million. It appears that BBPL has used banking facilities for raw
material procurement.
Financial Projection (FY14-FY18)
CBG has provided us projections for the above mentioned period. The underlying assumptions are 20% growth in sales
volume, while gross profit margin is expected to be stagnant at its existing level of 39%. Stocks & trade debts are expected to
enhance by 17% & 13% respectively. Noncurrent assets are forecasted to be enhanced by 3-8% annually. In the projections,
Burj Banks proposed exposure is reflected with decreasing trend over the years. On the whole, financial projection appears
to be reasonable with projected growth in line with current trend of the company and Pharma industry.
Conclusion:
Overall financial position of the company appears to be adequate with respect to Burj Banks existing & proposed exposure.
It is worth noting that BPPLs requested facility wont enhance its leverage position as it is a swap case. During one year
grace period, BPPL will pay only profit, which is expected to be Rs.23.2 Million or Rs.1.9 Million per month. Keeping in view
the growing sales, profitability and EBITDA, we understand that BPPLs financial position is adequate enough.

SAFETY ASSESSMENT

Obligor Profile /
Relationship
History
Brookes Pharma (Private) Limited (BPPL) was established in 1984 and deals in manufacturing of
pharmaceutical products. BPPL specializes in antibiotics, liver products, hair, skin and
cardiovascular areas. BPPL has recently obtained manufacturing license from two multinational
pharmaceutical companies namely M/s Merz & Co & M/s Edmond Pharma to produce active
pharmaceutical ingredients and finished products. BPPL has total staff strength of over 800
persons including 500 in sales and marketing department. The product portfolio of Brookes
includes medicines under product lines of gastro-enterology, anesthesia, dermatology, cardiology,
NSAID and ant-septic drugs. Brookes is an ISO 9001, ISO 14001, SA 8000 and OHSAS 18001
certified company. It is further upgrading its operations to get one more certification of ISO 17025
during the end of the year 2012.

Account History with Burj Bank
Burj Bank has approved DM/Murabaha/LC/LG and DM (Fleet Financing) facilities to the tune of
Rs.275 Million. Its facilities were renewed/reviewed for another year in October 2013. Overall
account history is modest with few instances of overdue up to 5-10 days. Burj Bank net earnings
from this client in FY13 are Rs.3.457 Million. It is relevant to mention that Burj Bank has also
financed BPPLs group concern i.e. Pharma Logistics to the tune of Rs.25 Million (DM Fleet), whose
o/s is reduced to Rs. 3.5 Million. Below is BPPLs import performance with Burj Bank.
Rupees in Million
FY12 FY13 FY14 (nine months)
62.89 125.42 85.02

CBG Rationale for
Enhanced Facility

CBG has requested for DM (Sales & purchase back) facility of Rs. 190 Million for swapping of
conventional banks/FIs exposure as detailed below.






FINANCING PROPOSAL SYNOPSIS
Financing & Investment Risk Department
Page 5 of 9
Rupees in Million
Sr. No. Name of Bank/FIs Exposure Size
01 Pak Brunei Investment Company 84.0
02 Pak Gulf leasing Company 32.0
03 Bank of Punjab 30.0
04 Silk Bank Limited 16.0
05 Orix Leasing Limited 30.0
Total 192.0

Client is interested in Islamic mode of financing and is in process of converting its financing
facilities to Islamic banks. It is to be noted that fresh DM (Sale & purchase back) facility is proposed
in line with already approved facility as its tenor is 6 years inclusive of one year grace period.
Detail of underlying assets is given in attached Annexure-B.
Management
Assessment
BPPL is a private limited company having following directorship.

Sr. No. Name of Director %Shareholding
01 Abdul Haseeb Khan 13.2%
02 Nadeem Khan 12.4%
03 Waseem Khan 12.4%
04 Saleem Khan 12.4%
05 Ishrat Haseeb 12.4%
06 Farhat Nadeem 12.4%
07 Nudrat Khan 12.4%
08 Roohi Saleem 12.4%
Total 100.0%

Mr. Abdul Haseeb Khan is the President/CEO of the company. He is an electrical engineer by
profession, having 45 years of experience including 25 years in pharmaceutical sector. Mr. Nadeem
Khan, Waseem Khan and Saleem Khan are working as Executive Directors, responsible for finance,
production and marketing function. Other directors are also adequately qualified and experienced
in their respective fields. The profile of top line management team, as given by CBG, is convincing
enough. It is relevant to mention that subject client is included in PEP list. However based on
clients reputation and Burj Banks relationship with the client, we attach acceptable management
risk with this name.
Business Risk
Analysis


Brookes Pharma (Private) Limited deals in manufacturing of pharmaceutical products. Some of its
leading products are Hepa Merz, Pyodine, Dostin, Coram etc. It deals in over 77 products. It is
worth noting that product concentration of Hepa-Merz & Pyodine constitutes 44% of total revenue.
It poses product concentration risk for the company. However, since BPPL does not face any
material competition, this risk is assessed to be mitigated. BPPLs end consumers are general
masses. BPPLs products are distributed throughout Pakistan through various distributors,
hospitals, pharmacies and retailers. Some of the key institutional buyers of BPPL are Armed
Forces, Aga Khan University Hospitals, PIMS and LNH. It may be noted that 55% of BPPLs sales are
distributed through its associate concern, Pharma Logistics. As reported earlier, Burj Bank has also
financed Pharma logistics for its fleet financing requirement.

It is relevant to mention that a thorough business risk analysis was conducted at the time of
initiation of financing relationship with this name, which was found in acceptable limits. Since then
no material change is observed in its business risk parameters, hence business risk associated with
this name may be considered acceptable.
Industry / Market
Risk Analysis

Industry analysis conducted by Business Unit adequately covers the market dynamics and industry
trend. We associate acceptable industry risk with the company based on growing demand and
limited competition in the organized segment within Pharma industry.
Security Analysis Security structure of existing facilities is same as already approved earlier, which is briefly
mentioned below.
DM (Sales & Purchase back)-I: 1
st
Pari Passu charge on all Present and Future Fixed Assets (Land,
Building and Plant & Machinery) amounting to Rs.200 Million inclusive of 25% risk margin.
Following are the security structure of Murabaha/LC (Sight/Usance), LG and DM (Fleet) facilities.

1
st
Pari Passu charge over present and future stock in trade and trade debts amounting to
Rs.100 Million inclusive of 25% risk margin.
Lien over import documents/Accepted BE.
FINANCING PROPOSAL SYNOPSIS
Financing & Investment Risk Department
Page 6 of 9
10% & 20% equity participation in the value of DM assets.
Title over DM financed asset (vehicle) & 6 Post Dated Cheques (PDC).
PG of directors.

Requested DM-II (Sales & Purchase back) of Rs. 190 Million is proposed against 1
st
PP charge on all
present and future fixed assets (land, building and plant & machinery) amounting to Rs. 267
Million inclusive of 25% risk margin. As per valuation dated July 24, 2013, following is the
valuation of fixed assets of BPPL.

Description Plot # 58, St. 15, Korangi Indus Plot # 59, St. 15, Korangi Indus
Rs. in Million
Market Value FSV Market Value FSV
Land 250.0 200.0 250.0 200.0
Building 210.8 168.7 126.3 101.0
Machineries 580.5 406.4 270.0 189.0
Total 1,041.3 775.1 646.3 490.0

Total market and FSV of fixed assets is Rs.1,687.6 Million and Rs.1,265.1 Million respectively. As
per Search Report dated 18.03.14, following banks enjoy PP over fixed assets of the company.
Rupees in Million
Sr.
No.
Banks Name Charge
Amount
O/s Amount Nature of Charge
01 Askari Bank Limited 100.0 - 1
st
EM over fixed assets
02 HMB 100.0 - 1
st
PP charge over fixed assets
03 SCB 150.0 117.0 1
st
PP charge over fixed assets
04 Pak Kuwait Inv. Co. 134.0 83.0 1
st
PP charge over fixed assets
05 Pak Brunei Inv. Co 267.0 84.0 1
st
PP charge over fixed assets
06 Silk Bank Limited 120.0 16.0 1
st
PP charge over fixed assets
07 Burj Bank Limited 200.0 137.5 1
st
PP charge over fixed assets
08 Bank of Punjab 200.0 30.0 1
st
PP charge over fixed assets
09 HBL 100.0 - 1
st
PP charge over fixed assets
Total 1,371.0 467.5

Adequate cushion is available with respect to market value of the assets & present o/s figures. CBG
has committed that after swapping of the existing facilities, charge over fixed assets of respective
banks will be vacated. Since Pak Gulf Leasing Limited and Orix Leasing Limited charges are not
reflected in the search report, BPPL will provide us an undertaking from respective FIs regarding
vacation of charge.
Pricing Pricing of DM-II facility is proposed as per already approved DM-I facility i.e. MK+2.1%. However
pricing of Murabaha is proposed to be reduced to 1.75% from 2% over KIBOR. FIRD forward this
synopsis at already approved pricing. As per current KIBOR benchmark, Burj Banks earning from
this client in grace period and repayment tenor is expected to be Rs.23.2 Million & 66.3 Million.
ECIB Reports We have ECIB report dated April 24, 2014 of BPPL, its other group concerns and their directors, in
which exposure as on March 31, 2014 is reported. As per these reports, BPPLs funded and non
funded exposure is Rs.1,264.227 Million & Rs.348.347 Million respectively. There is no mention of
any overdue, amount under litigation or reschedule/restructured exposure. ECIB reports of its
group companies and their directors are also clean.
Risk Rating As per CBG, BPPLs risk rating is 3/good with 75 score. FIRD reassessed its rating, which yields it
same as that of CBG with 73 points. CBG agrees with FIRD working.
FRR Scorecard



Following is the FRRS of the proposed and existing facilities.

Nature of Facility Facility Score Facility Grade
DM (Sale & Purchase
back)
65 C
Murabaha Facility 71 C
DM (Fleet) 88 B
Facilities With
Other Bank/FIs
BPPL is presently availing financing facilities from following banks/FIs.

Rupees in Million
Sr. No.
Name of Bank/FIs Nature of Facility Fund Based Limit
NFB Limits Total Limits
01 Askari Bank Ltd FATR/LC 15.0 55.0 70.0
02 HMBL Short Term/LC 50.0 40.0 90.0
03 SCB
Short & Long Term
370.0 105.0 475.0
FINANCING PROPOSAL SYNOPSIS
Financing & Investment Risk Department
Page 7 of 9
04 Silk Bank Limited
Short & Long Term
35.0 110.0 145.0
05 Pak Kuwait
Short & Long Term
164.0 - 164.0
06 Pak Brunei
Short & Long Term
200.0 - 200.0
07 Burj Bank
Short & Long Term
200.0 75.0 275.0
08 Bank of Punjab
Short & Long Term
130.0 70.0 200.0
09 HBL
Short & Long Term
50.0 100.0 150.0
10 Bank Islami Leasing 37.0 - 37.0
11 Pak Gulf Leasing 88.0 - 88.0
12
First Habib Modaraba
Leasing 30.0 - 30.0
13 Orix Leasing Leasing 68.0 - 68.0
Total 1,437.0 550.0 1,992.0

SBP PR-5 is fully complied with. After taking into consideration requested facility of Rs. 190
Million, Burj Banks proposed exposure of Rs. 461 Million will become second highest after SCB.
Further Requests


CBG has requested for gradual increase in LC/Murabaha limit corresponding to decrease in DM-I
exposure up to Rs. 125 Million. FIRD is not supportive of this arrangement in view of the fact that
such arrangement may pose monitoring repercussion, further, overall exposure over customer
shall not reduce and the payments made under the DM through cash flows may again be re-availed
under short term facility to finance working capital.

CONCLUSION/RECOMMENDATION:
Brookes Pharma (Private) Limited (BPPL) was established in 1984 and deals in manufacturing of pharmaceutical products.
BPPL specializes in antibiotics, liver products, hair, skin and cardiovascular areas.

Burj Bank has approved DM/Murabaha/LC/LG and DM (Fleet Financing) facilities to the tune of Rs. 275 Million. Its facilities
were earlier renewed/reviewed till October 2014. Overall account history is satisfactory with few isolated instances of
overdue up to 10 days. It is relevant to mention that Burj Bank has also financed its group concern i.e. Pharma Logistics to
the tune of Rs. 25 Million (DM Fleet financing). Customer has requested long term DM (Sale & Purchase back) facility of Rs.
190 Million, for swap of outstanding exposure from their conventional banks/FIs.

Based on the analysis carried out above, and due to adequate financial position and security structure, CBGs request for DM-
II (Sale & Purchase back) facility of Rs.190 Million is recommended for approval subject to compliance with all the terms and
conditions as per attached Annexure-A.

Recommended By:




______________________ ___________________________ __________________________
Financing Analyst Sr. Financing Analyst Sr. Financing Analyst
MANAGEMENT FINANCING COMMITEE




Chief Risk
Officer
Chief Financial
Officer
Group Head-
Treasury
Group Head
Corporate
Group Head-Retail
& Consumer
Approved
Not Approved
Others
Approved
Not Approved
Others
Approved
Not Approved
Other
Approved
Not Approved
Other
Approved
Not Approved
Others
Chief Executive Officer / President


Approved
Not Approved
Others
Comments:






FINANCING PROPOSAL SYNOPSIS
Financing & Investment Risk Department
Page 8 of 9
Annexure-A
Terms & Conditions
Conditions Precedent

1. Disbursement of the facility is subject to the submission/compliance of following:
a. Personal Guarantees of directors with their itemized & detailed PNWS covering the existing and enhanced
exposure.
b. Shariah approved MO for fresh financing facility.
c. Availability of letter regarding confirmation of principal o/s of Pak Brunei Investment Company, Pak Gulf
leasing Company, Bank of Punjab, Silk Bank Limited & Orix Leasing Limited.
d. Availability of fresh dated valuation of fixed assets of BPPL.
e. Availability of financial projection (FY19-FY20).
f. Availability of undertaking from BPPL that it will adjust complete profit and partial principal (if any) of
above mentioned banks/FIs from its own sources and vacate the charge of the banks within 15 days from
the date of disbursement.
g. Disbursement must be executed after perfection of 1
st
PP charge over present and future fixed assets of
BPPL. No deferral request will be entertained in this regard.
h. Joint visit/inspection by FIAD & CBG of the underlying DM assets and BPPLs operational set up to check
operational status of the DM assets and factory.
2. Confirmation in writing as to acceptance of facilities should be obtained from customer. In case customers
acceptance is not received within 30 days of the issue date of customer advising letter, the approval terms would
stand canceled.
Further Conditions Precedent (Controlling Covenants)
1. Fresh approved DM-II (Sale & Purchase back) facility is available for swapping of principal portion of above
mentioned banks/FIs only.
2. BPPL would route its business cash commensurate to the size of the financing accommodations with Burj Bank
during the currency of the facilities.
3. BPPL would route its import business equivalent to twice of its approved limits with Burj Bank.
4. The DM financed assets/fixed assets of BPPL must be kept fully insured for full market value at all times against
pertinent risks by any of the Insurance/ Takaful companies on the approved panel of Burj Bank.
5. The facility will be available for first utilization till July 31, 2014 i.e. if utilization is not made within stipulated
period, the facility would be considered withdrawn/cancelled. Full utilization is to be made within August 30, 2014.
6. Overall accommodation of BPPL shall remain restricted at Rs. 460.9 Million. Moreover, DM is non-revolving limit
and no disbursement should be allowed subsequent to full utilization of limit.
7. It must be ensured that total accommodation of BPPL should stand complied with the prescribed benchmarks
mentioned in the Prudential Regulations No. R-5 at all times during the currency of the approved limit.
8. All Insurance/ Takaful policies along with premium paid receipt must be held by the bank. All charges, insurance to
be recovered from customer upfront.
9. Customer must submit financial accounts within six months of the close of each financial year.
10. SBP Prudential Regulations and financing restrictions along with Banks financing policy, as advised by Burj Banks
Head Office from time to time and the instructions of approved product policy manuals, must be complied with at all
times.
11. During the tenancy of Burj Banks exposure, any change in directorship will require prior consent, in writing, from
the Bank. In the event of non-compliance with this condition Burj Bank will have the right to immediately recall the
facilities/ exposure arrangements.
12. Burj Bank reserves the right, acting on its own discretion, to cancel financing facilities approved by virtue of this
Approval anytime without assigning reason.
13. The bank shall have the bankers lien and right-off set-off on all deposits, accounts, properties & securities available
with Burj Bank.
14. The Bank reserves the right to recall all financing facilities at any time if the same are utilized for:
any purpose other than for which the facility was originally extended or
purposes detrimental to public interest or
Purposes against Shariah or the Law of the Land.
Note:
1. Review/renewal date of the facilities shall be May 31, 2015. CBG must submit its renewal/review proposal two month prior to
its due date.
2. CBG would ensure to review appropriateness of customers rating on a continuous basis, preferably on quarterly basis, and
submit downgrading / upgrading of account to FIRD in light of any material change in information.
3. All other terms and conditions as per earlier approvals will remain applicable and effective.


FINANCING PROPOSAL SYNOPSIS
Financing & Investment Risk Department
Page 9 of 9
Annexure-B

Detail of underlying DM assets
Rupees in Million
Sr. No. Nature of Assets Amount
01 Building Plot # 59 126.0
02 Inspection Machine 39.0
03 Dry Head Sterilizer 15.0
04 BQS Bilster Mac 12.0
05 Tablets & Capsules cartooning machine 11.5
06 Emulsifying Mixer & Storage Tank 9.0
Total 212.5